ZTS: Symmetrical Triangle detected on 28 Jul 2026

ZTS is forming a symmetrical triangle with a structure score of 14.0 and breakout score of 13.0, suggesting moderate pattern cohesion. The stock trades at $76.92 with resistance at $75.70 and support at $74.20. Volume is weak at 3.5M shares (61% of 20-day average, relative volume 0.60), which reduces pattern conviction. RSI sits at 52.35—neutral, neither overbought nor oversold. The stock is down 33.72% over three months but up 2.74% in two weeks, indicating early consolidation after a steep decline. The 69.07% win probability and overall 76.0 score reflect a setup worth monitoring, though volume confirmation will be critical for a sustained breakout.

ZTS suffered a severe shock on May 7, 2026, when Q1 2026 earnings revealed significant challenges in its Companion Animal segment. The first quarter financial results showed significant decline across its Companion Animal business, and the stock price fell 21.5%. Pet owners demonstrated increased price sensitivity resulting in a decline in veterinary visits, and competition intensified across key pet care categories including dermatology and parasiticides. Stifel lowered its price target on Zoetis to $95 from $105 and maintains a Hold rating. Argus analyst downgraded Zoetis to Hold from Buy. These analyst downgrades and ongoing litigation (class action filed mid-July 2026) create persistent headwinds. The May decline triggered the earlier double-bottom pattern (exceptional quality, 39.0 score) and subsequent consolidation, positioning this triangle as a potential recovery test.

A successful breakout above $75.70 resistance targets $80.41 (the conservative measured move), representing 4.5% upside from current price. Volume must expand above the 5.7M 20-day average to validate breakout conviction; current trading at 0.60 relative volume is insufficient. Invalidation occurs below $74.20 support, which would trigger a breakdown and likely retest of the May lows near $67.00. With a 69.07% win probability, the pattern suggests better odds than random, but the preceding -33.72% three-month decline and weak recent volume (only 2.74% ATR volatility) imply skepticism about upside momentum. The setup indicates a minor relief bounce scenario rather than a structural reversal.

Multiple material risks overshadow this technical setup. Analysts are adjusting price targets downward amid concerns about revenue declines in the companion animal segment. Securities litigation is active with a class action lead plaintiff deadline of July 27, 2026. Earnings are not expected until Q2 reporting, leaving fundamental uncertainty unresolved. 2026 guidance anticipates only 2%-5% organic growth, with competitive and macro headwinds persisting. With beta at 1.07 and 20-day volatility at 27.39%, downside moves could be sharp if sentiment deteriorates. Volume remains depressed (61% of average), suggesting weak institutional commitment to any breakout attempt. The combination of weakened earnings, downgraded analyst targets, and litigation risk creates significant downside tail risk if the triangle breaks below support.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.